Benzinga | May 13, 2021 04:01PM EDT

MedTech Round Up: Update On Johnson & Johnson, Becton Dickinson, Labcorp, Second Sight Medical, Biocept

Johnson & Johnson's (NYSE: JNJ) Vision segment has won FDA approval for the first contact lenses designed to reshape the cornea curve and help treat the progression of myopia in children.

* Designed to be worn overnight, the Acuvue Abiliti orthokeratology lenses are specifically fitted to match each eye, including people with and without astigmatism.

* Price Action: JNJ shares are trading 1.41% higher at $170.57 during the market session on the last check Thursday.

Becton Dickinson and Co (NYSE: BDX) has received a CE mark for its HPV screening from at-home self-collected vaginal samples using BD Onclarity HPV Assay.

* The assay can detect and identify 14 high-risk human papillomavirus (HPV) types in a single analysis and provide genotyping information.

* Price Action: BDX shares are trading 1.33% higher at $244.85 during the market session on the last check Thursday.

The FDA has granted Emergency Use Authorization for its Pixel by Labcorp (NYSE: LH) COVID-19 PCR test home collection kit for ages 2-17.

* The authorization expands the use of Pixel by Labcorp to children and adolescents two years of age and older.

* Price Action: LH shares are trading 1.97% higher at $277.26 during the market session on the last check Thursday.

Second Sight Medical Products Inc (NASDAQ: EYES) has received year three funding for its Orion Trial from the National Institutes of Health (NIH).

* The NIH released $1.4 million of the $6.4 million planned five-year grant.

* This notice of grant award follows promising two-year data from the Orion trial.

* Price Action: EYES shares are trading 20.5% lower at $5.07 during the market session on the last check Thursday.

Biocept Inc (NASDAQ: BIOC) has entered into a controlled equity offering with Cantor Fitzgerald & Co to sell up to $25 million of its common stock.

* It reported a Q1 EPS of $0.19, a turnaround from a $(1.06) loss a year ago. Revenues of $17.7 million compared to $1.4 million in Q1 2020 were well above the consensus of $13.7 million.

* The increase is attributable to higher RT-PCR COVID-19 testing.

* Price Action: BIOC shares are trading 9.9% lower at $4.29 during the market session on the last check Thursday.